Maaike Fransen

Failure Analysis Engineer at Insulet Corporation
  • Claim this Profile
Contact Information
us****@****om
(386) 825-5501
Location
Tilburg, North Brabant, Netherlands, NL

Topline Score

Topline score feature will be out soon.

Bio

Generated by
Topline AI

You need to have a working account to view this content.
Join now
You need to have a working account to view this content.
Join now

Credentials

  • Systems Engineering
    Mikrocentrum
    Apr, 2023
    - Nov, 2024
  • Innovation management game
    Technische Universiteit Eindhoven
    Jun, 2018
    - Nov, 2024

Experience

  • Insulet Corporation
    • United States
    • Medical Equipment Manufacturing
    • 700 & Above Employee
    • Failure Analysis Engineer
      • Apr 2022 - Present

      As Failure Analysis Engineer at Insulet Netherlands B.V., I have a hands-on engineering role conducting post market investigations of the FDA approved medical device, the Omnipod. My tasks also include writing official documents (e.g., quality work instructions, validation protocols and reports), providing equipment and process training, lot qualification testing and documenting, and assisting during audits. As Failure Analysis Engineer at Insulet Netherlands B.V., I have a hands-on engineering role conducting post market investigations of the FDA approved medical device, the Omnipod. My tasks also include writing official documents (e.g., quality work instructions, validation protocols and reports), providing equipment and process training, lot qualification testing and documenting, and assisting during audits.

  • CUTISS AG
    • Switzerland
    • Biotechnology Research
    • 1 - 100 Employee
    • Early-Stage Researcher
      • May 2021 - Aug 2021

      Cutiss AG has developed denovoSkin™ to increase the quality of life of patients with skin defects (e.g. burns). As denovoSkin™ lacks pigmentation, Cutiss AG aims to develop a robust platform for the isolation, characterization and in vitro expansion of patient-derived melanocytes. The 3-year doctorate program is part of the Innovative Training Network “SkinTERM”, an EU Horizon 2020 Marie Skłodowska-Curie Actions funded project. Cutiss AG has developed denovoSkin™ to increase the quality of life of patients with skin defects (e.g. burns). As denovoSkin™ lacks pigmentation, Cutiss AG aims to develop a robust platform for the isolation, characterization and in vitro expansion of patient-derived melanocytes. The 3-year doctorate program is part of the Innovative Training Network “SkinTERM”, an EU Horizon 2020 Marie Skłodowska-Curie Actions funded project.

Education

  • Technische Universiteit Eindhoven
    MSc, Biomedische technologie (Biomedical engineering)
    2017 - 2020
  • Technische Universiteit Eindhoven
    BSc, Biomedische technologie (Biomedical engineering)
    2014 - 2017

Community

You need to have a working account to view this content. Click here to join now